RSV
Biotech

Pfizer axes another RSV med picked up in $525M ReViral buy

In another blow to its $525 million ReViral buy, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat RSV.
Gabrielle Masson Oct 8, 2024 4:58pm
circle

Boehringer inks $607M Circle pact for preclinical cancer program

Oct 9, 2024 8:36am
Pac man eat MA deal buy sell merger

With Kezar in lupus limbo, Concentra spies potential acquisition

Oct 9, 2024 7:10am
Filling hands with water from a clear and cold mountain spring

Purespring bottles up $105M series B for kidney gene therapy

Oct 9, 2024 2:00am
Braslia Federal District Brazil view of Lake Parano with government buildings and the Cathedral

GEMMABio gene therapy heads to Brazil with $100M government deal

Oct 8, 2024 1:43pm
Medtronic headquarters

Medtronic recalls MiniMed insulin pumps over drained batteries

Oct 8, 2024 12:00pm
Medtech News

FDA clears at-home COVID/flu combo test with eye on fall season

Oct 8, 2024 11:05am

FDA pulse oximeter guidance unlikely to end years of racial bias

Oct 8, 2024 10:58am

Seizure-spotting headset maker Ceribell seeks $101M Nasdaq IPO

Oct 7, 2024 11:30am

MARAbio’s antibody test for autoimmune-related autism nets $19M

Oct 7, 2024 10:00am